Reply to the letter to the editor'What is the clinical impact ofthe LUX-Lung 5 trial?' by Addeo

M. Schuler; J. C.H. Yang; D. Planchard

doi:10.1093/annonc/mdw144

Reply to the letter to the editor'What is the clinical impact ofthe LUX-Lung 5 trial?' by Addeo

M. Schuler, J. C.H. Yang, D. Planchard

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	1172-1173
Nombre de pages	2
journal	Annals of Oncology
Volume	27
Numéro de publication	6
Les DOIs	https://doi.org/10.1093/annonc/mdw144
état	Publié - 18 juin 2016

Accès au document

10.1093/annonc/mdw144

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{cb56f4cd13f14c5f9fd8a4dfedb35db2,

title = "Reply to the letter to the editor'What is the clinical impact ofthe LUX-Lung 5 trial?' by Addeo",

author = "M. Schuler and Yang, {J. C.H.} and D. Planchard",

note = "Funding Information: This work was supported by Boehringer Ingelheim. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard of GeoMed, an Ashfield Company, part of UDG Healthcare plc, during the preparation of this article. There is no applicable grant number. Funding Information: This work was supported by Boehringer Ingelheim . Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard of GeoMed , an Ashfield Company , part of UDG Healthcare plc , during the preparation of this article. There is no applicable grant number. ",

year = "2016",

month = jun,

day = "18",

doi = "10.1093/annonc/mdw144",

language = "English",

volume = "27",

pages = "1172--1173",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "6",

}

TY - JOUR

T1 - Reply to the letter to the editor'What is the clinical impact ofthe LUX-Lung 5 trial?' by Addeo

AU - Schuler, M.

AU - Yang, J. C.H.

AU - Planchard, D.

N1 - Funding Information: This work was supported by Boehringer Ingelheim. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard of GeoMed, an Ashfield Company, part of UDG Healthcare plc, during the preparation of this article. There is no applicable grant number. Funding Information: This work was supported by Boehringer Ingelheim . Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard of GeoMed , an Ashfield Company , part of UDG Healthcare plc , during the preparation of this article. There is no applicable grant number.

PY - 2016/6/18

Y1 - 2016/6/18

UR - http://www.scopus.com/inward/record.url?scp=84974817848&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw144

DO - 10.1093/annonc/mdw144

M3 - Letter

C2 - 27029703

AN - SCOPUS:84974817848

SN - 0923-7534

VL - 27

SP - 1172

EP - 1173

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -